TY - JOUR
T1 - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
AU - Ledermann, Jonathan
AU - Harter, Philipp
AU - Gourley, Charles
AU - Friedlander, Michael
AU - Vergote, Ignace
AU - Rustin, Gordon
AU - Scott, Clare
AU - Meier, Werner
AU - Shapira-Frommer, Ronnie
AU - Safra, Tamar
AU - Matei, Daniela
AU - Macpherson, Euan
AU - Watkins, Claire
AU - Carmichael, James
AU - Matulonis, Ursula
PY - 2012
Y1 - 2012
N2 - Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.
AB - Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.
UR - http://www.scopus.com/inward/record.url?scp=84859523588&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1105535
DO - 10.1056/NEJMoa1105535
M3 - Article
C2 - 22452356
VL - 366
SP - 1382
EP - 1392
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 15
ER -